VYNE Therapeutics Inc. (VYNE) Financials

VYNE Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 25.9 million 1.2 million
Dec. 31, 2025 30.2 million 2.4 million
Sept. 30, 2025 36.1 million 4.0 million
June 30, 2025 44.7 million 5.8 million

VYNE Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -4.1 million 474000
Dec. 31, 2025 -3.8 million 529000
Sept. 30, 2025 -7.1 million 487000
June 30, 2025 -10.8 million 529000

VYNE Net Income

No data available :(

VYNE Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 24.9 million - -
Dec. 31, 2025 29.0 million - -
Sept. 30, 2025 32.7 million - -
June 30, 2025 39.6 million - 25000

VYNE Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 42.8 million
Dec. 31, 2025 42.8 million
Sept. 30, 2025 42.7 million
June 30, 2025 42.8 million

VYNE Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 817000 3.1 million -
Dec. 31, 2025 - 3.0 million 2.4 million -
Sept. 30, 2025 - 5.3 million 2.7 million -
June 30, 2025 - 4.9 million 2.7 million -

VYNE Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 86000 6000
Dec. 31, 2025 130000 5000
Sept. 30, 2025 169000 12000
June 30, 2025 69000 6000

VYNE Revenue by Segment
Graph available only for paid members. Upgrade to see it.

VYNE

Price: $0.51

52 week price:
0.28
1.60

Earnings Per Share: -0.51 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 68900

Market Capitalization: 11.3 million

Links: